Published in
American Association for Cancer Research, Clinical Cancer Research, 11(26), p. 2439-2440, 2020
DOI: 10.1158/1078-0432.ccr-20-0707
Links
Tools
Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Abstract PARP inhibitors (PARPi) are promising in BRCA2-altered prostate cancer. Data were presented on PARPi efficacy in prostate cancers with alterations in other DNA damage repair genes which suggest low response rates in ATM-, CHEK2-, CDK12-altered tumors and promising results in PALB2-, RAD51B-, FANCA-, and BRIP1-altered tumors. See related article by Abida et al., p. 2487